CG
ACAD icon

Cutler Group’s Acadia Pharmaceuticals ACAD Stock Holding History

Cutler Group’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-26,200
Closed -$28K – 4283
2022
Q3 		$28K Buy
+26,200
New +$424K ﹤0.01% 2340
2022
Q2 		– Sell
-5,300
Closed -$10K – 4868
2022
Q1 		$10K Sell
5,300
-90,000
-94% -$2.18M ﹤0.01% 3584
2021
Q4 		$25K Buy
95,300
+75,100
+372% +$1.51M ﹤0.01% 2934
2021
Q3 		$3K Buy
+20,200
New +$389K ﹤0.01% 4738
2021
Q2 		– Sell
-3,200
Closed -$4K – 5571
2021
Q1 		$4K Buy
3,200
+2,900
+967% +$128K ﹤0.01% 4451
2020
Q4 		$4K Buy
+300
New +$14.9K ﹤0.01% 3739
2020
Q3 		– Sell
-3,500
Closed -$9K – 4588
2020
Q2 		$9K Sell
3,500
-1,800
-34% -$86.4K ﹤0.01% 2915
2020
Q1 		$22K Buy
5,300
+5,000
+1,667% +$206K ﹤0.01% 2228
2019
Q4 		$3K Sell
300
-16,000
-98% -$696K ﹤0.01% 3228
2019
Q3 		$7K Buy
16,300
+800
+5% +$24.3K ﹤0.01% 2800
2019
Q2 		$58K Buy
+15,500
New +$396K 0.01% 1434
2019
Q1 		– Sell
-3,500
Closed -$4K – 3934
2018
Q4 		$4K Sell
3,500
-8,800
-72% -$171K ﹤0.01% 2990
2018
Q3 		$65K Sell
12,300
-14,900
-55% -$234K ﹤0.01% 1439
2018
Q2 		$7K Sell
27,200
-400
-1% -$7.13K ﹤0.01% 2871
2018
Q1 		$6K Buy
27,600
+19,800
+254% +$548K ﹤0.01% 3131
2017
Q4 		$8K Sell
7,800
-13,400
-63% -$429K ﹤0.01% 3273
2017
Q3 		$102K Sell
21,200
-23,200
-52% -$755K ﹤0.01% 1659
2017
Q2 		$55K Buy
44,400
+17,800
+67% +$530K ﹤0.01% 2390
2017
Q1 		$25K Sell
26,600
-214,300
-89% -$7.56M ﹤0.01% 3095
2016
Q4 		$140K Buy
240,900
+159,000
+194% +$4.21M 0.01% 1597
2016
Q3 		$128K Buy
81,900
+47,700
+139% +$1.62M 0.01% 1610
2016
Q2 		$140K Sell
34,200
-56,200
-62% -$1.88M 0.01% 1394
2016
Q1 		$340K Sell
90,400
-33,000
-27% -$720K 0.02% 706
2015
Q4 		$287K Buy
+123,400
New +$4.35M 0.02% 912

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AWA
Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Cutler Group's ACAD Position: Q3 2022 in Review

Cutler Group sold out of Acadia Pharmaceuticals (ACAD) in Q3 2022, closing a stake of 800 shares — an estimated $13K sold.

Cutler Group first reported a position in ACAD in Q4 2015 and held it in 21 quarters. The position peaked at $1.62M in Q1 2017. 222 funds tracked by Wall St. Rank hold ACAD as of Q3 2022.

  • Cutler Group reported no remaining Acadia Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Cutler Group sold 800 Acadia Pharmaceuticals shares in Q3 2022, an estimated $13K.
  • Cutler Group first reported a position in Acadia Pharmaceuticals in Q4 2015 and held it in 21 quarters.
  • Cutler Group's Acadia Pharmaceuticals position peaked at $1.62M in Q1 2017.
  • 222 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2022.

Based on Cutler Group's 13F filing for Q3 2022, filed 25 Oct 2022.